$262 Million is the total value of Aisling Capital Management LP's 13 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 7.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio (BBIO) | $130,095,000 | +12.4% | 3,989,412 | 0.0% | 49.65% | -1.5% | |
| EIDX | Eidos Therapeutics, Inc. (EIDIX) | $53,563,000 | -2.7% | 1,123,630 | 0.0% | 20.44% | -14.8% | |
| AVRO | AVROBIO, Inc. (AVRO) | $17,621,000 | +12.1% | 1,009,779 | 0.0% | 6.72% | -1.8% | |
| AGLE | Buy | Aeglea Biotherapeutics Inc (AGLE) | $15,643,000 | +160.0% | 1,691,151 | +31.0% | 5.97% | +127.8% |
| SNDX | Buy | Syndax Pharmaceuticals Inc. (SNDX) | $15,191,000 | +58.3% | 1,025,000 | +17.1% | 5.80% | +38.6% |
| BCEL | Atreca (BCEL) | $8,249,000 | +28.6% | 387,653 | 0.0% | 3.15% | +12.6% | |
| OBSV | ObsEva SA (OBSV) | $8,166,000 | +144.4% | 1,386,338 | 0.0% | 3.12% | +114.2% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $4,140,000 | +8.9% | 2,000,000 | 0.0% | 1.58% | -4.5% | |
| SNSS | Sunesis Pharmaceuticals, Inc. (SNSS) | $2,660,000 | -36.5% | 10,100,000 | 0.0% | 1.02% | -44.4% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $2,328,000 | +52.4% | 2,718,226 | 0.0% | 0.89% | +33.3% | |
| VRNA | Verona Pharma plc (VRNA) | $2,072,000 | +13.3% | 443,596 | 0.0% | 0.79% | -0.6% | |
| Nabriva Therapeutics plc (NBRV) | $1,289,000 | +17.4% | 1,910,287 | 0.0% | 0.49% | +2.9% | ||
| ACRS | Aclaris Theraputics Inc (ACRS) | $1,028,000 | +55.8% | 634,455 | 0.0% | 0.39% | +36.1% | |
| RCUS | Exit | Arcus Biosciences, Inc. (RCUS) | $0 | – | -333,333 | -100.0% | -2.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.